← All trials
NCT05351801
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2023
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2027
- First posted
- Apr 28, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 320
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Department of Veteran AffairsLead sponsor
- South Texas Health Care System, San Antonio, TXOverall official - principal investigator
- Department of Veteran AffairsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.